AASLD

8-12 November, 2019
Boston, Massachusetts

ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.

During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV.

Read more »

Collaboration with the Swiss Institute of Bioinformatics

ENYO Pharma is pleased to announce the initiation of a bioinformatics collaboration with Lydie Lane and Amos Bairoch of the CALIPHO group, part of the SIB Swiss Institute of Bioinformatics and the University of Geneva. The CALIPHO group aims at using a combination of bioinformatics and experimental methodologies to increase the knowledge on human proteins. Together, we will integrate ENYO’s unique protein interactome datasets within neXtProt, a comprehensive human-centric discovery platform,

Read more »

Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference

22 October, 2019
New-York, USA

ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”

Read more »

International HBV Meeting

1-5 October, 2019
Melbourne, Australia

The ENYO Pharma team will be present in Melbourne in October to present, in collaboration with Pr. André’s Inserm team, a poster entitled “Interplay and Recruitment of FXR and HBx on cccDNA and Role on Viral Transcription” describing FXR mechanism of action in HBV inhibition.

Read more »

ENYO PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE

Lyon, France, September 19th, 2019 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. ENYO Pharma also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).

Read more »